NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BEAM

Beam Therapeutics Inc

Jun 30 • 04:00PM ET

17.01

Dollar change +0.21
Percentage change 1.25	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA EDIT ALNY SRPT SGMO BLUE CLLS VYGR ADVM

| Held by: ARKK VTI IWM VB ARKG XBI VXF VBK IWO IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.61	Insider Own	10.88%	Shs Outstand	100.56M	Perf Week	1.80%
Market Cap	1.71B	Forward P/E	-	EPS next Y	-4.64	Insider Trans	-1.14%	Shs Float	89.62M	Perf Month	4.23%
Enterprise Value	648.66M	PEG	-	EPS next Q	-1.11	Inst Own	88.04%	Short Float	24.25%	Perf Quarter	-23.41%
Income	-387.34M	P/S	26.90	EPS this Y	-0.41%	Inst Trans	28.25%	Short Ratio	9.55	Perf Half Y	-40.96%
Sales	63.58M	P/B	1.52	EPS next Y	-0.83%	ROA	-27.41%	Short Interest	21.73M	Perf YTD	-31.41%
Book/sh	11.17	P/C	1.40	EPS next 5Y	-0.84%	ROE	-38.04%	52W High	35.25 -51.74%	Perf Year	-31.52%
Cash/sh	12.13	P/FCF	-	EPS past 3/5Y	7.43% -20.88%	ROIC	-30.55%	52W Low	13.52 25.77%	Perf 3Y	-59.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.00% 412.30%	Gross Margin	65.36%	Volatility	4.33% 5.97%	Perf 5Y	-35.47%
Dividend TTM	-	EV/Sales	10.20	EPS Y/Y TTM	-164.76%	Oper. Margin	-677.47%	ATR (14)	1.02	Perf 10Y	-
Dividend Ex-Date	Feb 04, 2014	Quick Ratio	8.81	Sales Y/Y TTM	-82.38%	Profit Margin	-609.24%	RSI (14)	47.82	Recom	1.39
Dividend Gr. 3/5Y	- -	Current Ratio	8.81	EPS Q/Q	-2.85%	SMA20	-0.83%	Beta	2.08	Target Price	43.44
Payout	-	Debt/Eq	0.14	Sales Q/Q	0.81%	SMA50	-3.86%	Rel Volume	0.67	Prev Close	16.80
Employees	483	LT Debt/Eq	0.13	Earnings	May 06 BMO	SMA200	-26.63%	Avg Volume	2.28M	Price	17.01
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-4.75% -46.70%	Trades		Volume	1,531,514	Change	1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy	$42
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$40
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform	$27 → $39
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy	$80
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120

Show Previous Ratings

Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
07:00AM	Loading…
Jun-13-25 07:00AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-05-25 11:30AM	Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 07:00AM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease (GlobeNewswire)
May-29-25 11:54PM	FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)' AATD Gene Therapy (Insider Monkey)
04:01PM	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-14-25 09:30AM	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress (GlobeNewswire)
07:00AM	Loading…
May-13-25 07:00AM	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-12-25 04:01PM	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)
12:41PM	Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates (Zacks)
12:25PM	Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up (Zacks)
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:55AM	NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up (Zacks)
08:06AM	Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut (Zacks)
May-08-25 12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks) +6.32%
12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks)
12:07PM	Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
08:59AM	Loading…
May-07-25 08:59AM	BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-06-25 05:05PM	Why Beam Therapeutics Stock Tanked on Tuesday (Motley Fool) -19.32%
01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks)
11:07AM	Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
09:17AM	RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates (Zacks)
08:20AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-05-25 04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
12:21PM	Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings (Zacks)
11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
May-01-25 10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
Apr-25-25 09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +7.29%
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -10.63%
Apr-07-25 10:06AM	Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease (Benzinga)
Apr-05-25 07:00AM	Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress (GlobeNewswire)
Apr-01-25 12:42PM	Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? (Insider Monkey) -9.70%
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
Mar-31-25 11:05AM	Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street (The Wall Street Journal) -12.07%
09:03AM	The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics (Zacks)
Mar-30-25 11:35AM	Street Calls of the Week (Investing.com)
Mar-28-25 09:39AM	Promising Genomics & Synthetic Biology Stocks to Consider in 2025 (Zacks)
09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 04:01PM	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration (GlobeNewswire)
11:30AM	Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-21-25 01:13PM	Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy (SeekingAlpha)
Mar-19-25 10:27AM	CRISPR Therapeutics Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Mar-16-25 10:58AM	Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? (Insider Monkey)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-10-25 09:24AM	Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? (Insider Monkey) -9.80%
08:25AM	Beam base editing therapy gets proof of concept in rare lung disease (BioPharma Dive)
06:01AM	Beam Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire)
06:00AM	Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation (GlobeNewswire)
Mar-04-25 09:00PM	Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% (Benzinga) +5.34%
Feb-25-25 08:15AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts (GlobeNewswire)
Feb-24-25 10:07AM	Cathie Wood buys $11 million of under-the-radar AI stock (TheStreet)
07:00AM	Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences (GlobeNewswire)
Feb-23-25 03:05PM	Why Beam Therapeutics Inc. (BEAM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-13-25 09:55AM	Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? (Zacks)
Feb-10-25 09:40AM	Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-25 07:00AM	Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference (GlobeNewswire) +5.29%
Jan-28-25 09:55AM	Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet (Zacks)
Jan-23-25 07:00AM	Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) -8.77%
10:29AM	Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? (Zacks)
07:00AM	Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts (GlobeNewswire)
Dec-30-24 03:27PM	Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-29-24 06:28AM	Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-17-24 07:00AM	Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 12:01PM	Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Dec-09-24 11:10AM	Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains (Benzinga)
07:15AM	ASH24: Darzalex in smoldering myeloma, Mercks ADC data and Novos sickle cell drug (BioPharma Dive)
Dec-08-24 01:45PM	Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-07-24 11:30AM	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire) +5.49%
Dec-05-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? (Zacks)
Dec-04-24 07:00AM	Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader (GlobeNewswire)
Nov-12-24 04:01PM	Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference (GlobeNewswire) -7.94%
Nov-07-24 06:26AM	Beam Therapeutics upgraded to Outperform from Market Perform at Leerink (TipRanks)
Nov-06-24 02:12AM	Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... (GuruFocus.com) +11.24%
01:40AM	Q3 2024 Beam Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-05-24 03:37PM	Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial (Benzinga)
09:00AM	Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bellon Christine	Chief Legal Officer	Apr 01 '25	Sale	18.35	5,674	104,122	117,294	Apr 03 09:53 PM
Evans John M.	CEO	Apr 01 '25	Sale	18.35	30,663	562,684	986,249	Apr 03 09:52 PM
Ciaramella Giuseppe	President	Apr 01 '25	Sale	18.35	7,434	136,418	190,216	Apr 03 09:51 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Apr 01 '25	Sale	18.35	3,015	55,330	44,512	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 02 '25	Sale	17.73	20,997	372,294	65,742	Apr 03 09:50 PM
Simon Amy	Chief Medical Officer	Apr 01 '25	Sale	18.35	9,566	175,542	86,739	Apr 03 09:50 PM
AMY SIMON	Officer	Apr 02 '25	Proposed Sale	17.73	20,997	372,294		Apr 02 04:08 PM
AMY SIMON	Officer	Apr 01 '25	Proposed Sale	22.21	30,562	678,782		Mar 31 06:44 PM
JOHN M. EVANS	Officer	Apr 01 '25	Proposed Sale	22.21	64,842	1,440,141		Mar 31 06:43 PM
CHRISTINE BELLON	Officer	Apr 01 '25	Proposed Sale	22.21	18,125	402,556		Mar 31 06:43 PM
GIUSEPPE CIARAMELLA	Officer	Apr 01 '25	Proposed Sale	22.21	23,750	527,488		Mar 31 06:43 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Feb 18 '25	Sale	35.00	6,287	220,045	37,527	Feb 20 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Option Exercise	7.22	10,000	72,200	112,968	Feb 19 04:10 PM
Bellon Christine	Chief Legal Officer	Feb 14 '25	Sale	34.00	10,000	340,000	102,968	Feb 19 04:10 PM
CHRISTINE BELLON	Officer	Feb 14 '25	Proposed Sale	34.00	10,000	340,000		Feb 14 04:06 PM
Evans John M.	CEO	Jan 30 '25	Sale	26.75	30,000	802,484	908,659	Feb 03 04:05 PM
JOHN M EVANS	Officer	Jan 30 '25	Proposed Sale	26.75	30,000	802,482		Jan 30 04:12 PM
Bellon Christine	Chief Legal Officer	Jan 02 '25	Sale	24.68	1,241	30,628	102,968	Jan 06 05:49 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Jan 02 '25	Sale	24.68	1,117	27,568	43,814	Jan 06 05:48 PM
BETHANY J. CAVANAGH	Officer	Dec 31 '24	Proposed Sale	25.27	9,500	240,065		Dec 30 07:29 PM
CHRISTINE BELLON	Officer	Dec 31 '24	Proposed Sale	25.27	4,167	105,300		Dec 30 07:26 PM
Ciaramella Giuseppe	President	Dec 17 '24	Option Exercise	0.67	53,500	35,845	162,650	Dec 19 04:10 PM
Ciaramella Giuseppe	President	Nov 06 '24	Sale	26.36	51,110	1,347,050	109,150	Nov 08 04:10 PM
Ciaramella Giuseppe	President	Oct 14 '24	Option Exercise	2.00	41,754	83,594	211,370	Oct 16 04:44 PM
Ciaramella Giuseppe	President	Oct 14 '24	Sale	26.27	51,110	1,342,752	160,260	Oct 16 04:44 PM
Giuseppe Ciaramella	Officer	Oct 14 '24	Proposed Sale	24.65	102,220	2,519,723		Oct 15 11:37 AM
Burrell Terry-Ann	Officer	Oct 07 '24	Proposed Sale	23.00	185,565	4,267,995		Oct 07 05:00 PM
Bellon Christine	Chief Legal Officer	Oct 01 '24	Sale	23.48	385	9,040	104,209	Oct 02 05:52 PM
Cavanagh Bethany J	SVP, Finance and Treasurer	Oct 01 '24	Sale	23.48	289	6,785	44,931	Oct 02 05:51 PM
Evans John M.	CEO	Sep 30 '24	Sale	24.60	60,000	1,476,024	938,659	Oct 02 05:49 PM
JOHN M EVANS	Officer	Sep 30 '24	Proposed Sale	24.60	60,000	1,476,024		Sep 30 04:51 PM
Simon Amy	Chief Medical Officer	Jul 02 '24	Sale	22.95	748	17,167	68,805	Jul 03 04:05 PM
Simon Amy	Chief Medical Officer	Jul 01 '24	Sale	23.76	502	11,928	69,553	Jul 03 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BEAM

Beam Therapeutics Inc

Upgrade your FINVIZ experience